Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation TCT 2012

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Presenter: Michael Maeng

October 23, 2012

Presentation Fellows 2012

Oral Antithrombin and Xa Inhibitors for ACS and PCI

Presenter: Michael Ezekowitz

April 22, 2012

Presentation PCI Outcomes 2012

PCI in NSTEMI and STEMI: Essentials of Pharmacology

Presenter: C. Michael Gibson

March 23, 2012

Presentation TCT 2012

Safety and Efficacy for the Use of Prasugrel in Patients Undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin.

Presenter: Ana Laynez, Rebecca Torguson, Camille Hauville, Gabriel Sardi, Itsik Ben-Dor, Gabriel Maluenda, Michael A. Gaglia, Manuel A. Gonzalez, Israel M. Barbash, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Presenter: Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld, Thorsten Schneider, Carlos Freitas, Michael Haude

January 03, 2012

Advertisement

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Oral Antithrombin and Xa Inhibitors for ACS and PCI

PCI in NSTEMI and STEMI: Essentials of Pharmacology

Safety and Efficacy for the Use of Prasugrel in Patients Undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin.

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content